News

09.02.2022
Launch of Generium’s Omalizumab Biosimilar for Atopic Bronchial Asthma  Marks Selexis’ Ninth Commercial Product  фото

Launch of Generium’s Omalizumab Biosimilar for Atopic Bronchial Asthma Marks Selexis’ Ninth Commercial Product

Third Biosimilar to Reach the Market Under Selexis/Generium Commercial License Agreements

28.01.2022
Expo 2020 in Dubai: Russian Pharma Industry Adapts to Pandemic, Open to Cooperation With Arab World фото

Expo 2020 in Dubai: Russian Pharma Industry Adapts to Pandemic, Open to Cooperation With Arab World

The 13th meeting of the Russian-Arab Business Council session was held on 25-26 January.
23.02.2021
Russia shows off new Covid-19 vaccine factory even as its people hesitate to get the shot фото

Russia shows off new Covid-19 vaccine factory even as its people hesitate to get the shot

Volginsky, Russia (CNN) — Decades ago, Soviet scientists researched biological weapons at a site in Volginsky, about 70 miles east of Moscow. Now, that site is being used to mass-produce a vaccine aimed at protecting people around the world from the coronavirus.
21.01.2021
Talks on production of Russian vaccine in Serbia commence фото

Talks on production of Russian vaccine in Serbia commence

Minister without portfolio in charge of innovations and technological development Nenad Popovic visited today the production capacities of the largest Russian vaccine manufacturer "Sputnik V" - Generium in the Vladimir region in Russia.
27.10.2020
GENERIUM launched the production of Sputnik V vaccine фото

GENERIUM launched the production of Sputnik V vaccine

Moscow, 26 October 2020. The Ministry of Health of the Russian Federation has included a biotechnology company GENERIUM in the marketing authorisation as a manufacturer of Gam-COVID-Vac (Sputnik V) vaccine for the prevention of COVID-19.
20.10.2020
First Russian omalizumab biosimilar registered for the treatment of severe bronchial asthma фото

First Russian omalizumab biosimilar registered for the treatment of severe bronchial asthma

Moscow, 19 October 2020. GENERIUM, a Russian biotechnology company, received a marketing authorisation (MA) for the first national biosimilar of a recombinant (genetically engineered) humanised monoclonal antibody (mAb) to immunoglobulin E (IgE)—omalizumab (Genolair®) for the treatment of persistent atopic bronchial asthma of mean and severe degree.
05.06.2020
GENERIUM became the first company registered a unique combination of high-precision tests for the detection of antibodies of three classes to the SARS-CoV-2 coronavirus (COVID-19) фото

GENERIUM became the first company registered a unique combination of high-precision tests for the detection of antibodies of three classes to the SARS-CoV-2 coronavirus (COVID-19)

Moscow, Russia, 5 June 2020. GENERIUM, a leading Russian biopharmaceutical company involved in the development and production of pharmaceutical products for the diagnosis and treatment of orphan, oncological and socially significant diseases has registered three unique test systems for the detection of specific anti-SARS-CoV-2 antibodies of the IgA, IgM and IgG classes by the enzyme-linked immunosorbent assay (ELISA).
28.04.2020
First licence for the production of biomedical cell products granted фото

First licence for the production of biomedical cell products granted

The Federal Service for Surveillance in Healthcare (Roszdravnadzor) issued the first Russian licence for the manufacture of biomedical cell products (BMCP). The Ministry of Industry and Trade of the Russian Federation announced that the licence was granted to the biotechnology company Generium JSC.
06.04.2020
GENERIUM registered an EXPRESS test for SARS-CoV-2 (COVID-19) фото

GENERIUM registered an EXPRESS test for SARS-CoV-2 (COVID-19)

Novosibirsk, Moscow, 6 April. An innovative express test for coronavirus infection of GENERIUM, a leading Russian biopharmaceutical company, developed by Medical Biological Union Group, was registered by the Federal Service for Surveillance in Healthcare and Social Development (Roszdravnadzor). This is the first national express test that allows determining the presence of coronavirus with an accuracy of more than 94% within 40 minutes, including sample preparation, using the standard equipment.
31.01.2020
Two Original Orphan Medicinal Products by GENERIUM  Approved for Clinical Studies фото

Two Original Orphan Medicinal Products by GENERIUM Approved for Clinical Studies

Moscow, Russia, 31 January 2020, GENERIUM, a Russian biopharmaceutical company involved in the development and commercialisation of pharmaceutical products for the treatment of orphan, oncological and socially significant diseases, received an authorization from the Russian healthcare authorities for clinical studies of two original medicinal products used in the treatment of hereditary angioedema and mucopolysaccharidosis type II (Hunter syndrome).
Еще новости